<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Alteogen Inc. — News on 6ix</title>
    <link>https://6ix.com/company/alteogen-inc</link>
    <description>Latest news and press releases for Alteogen Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 17 Sep 2025 07:40:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/alteogen-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68362d5c78dffbe2df1466a2.webp</url>
      <title>Alteogen Inc.</title>
      <link>https://6ix.com/company/alteogen-inc</link>
    </image>
    <item>
      <title>Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)</title>
      <link>https://6ix.com/company/alteogen-inc/news/alteogen-receives-european-commission-approval-for-aflibercept-biosimilar-eyluxvir-alt-l9</link>
      <guid isPermaLink="true">https://6ix.com/company/alteogen-inc/news/alteogen-receives-european-commission-approval-for-aflibercept-biosimilar-eyluxvir-alt-l9</guid>
      <pubDate>Wed, 17 Sep 2025 07:40:00 GMT</pubDate>
      <description>Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary, Alteogen Biologics.</description>
    </item>
    <item>
      <title>Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, &apos;EYLUXVI® (ALT-L9)&apos;</title>
      <link>https://6ix.com/company/alteogen-inc/news/alteogen-receives-positive-chmp-opinion-for-aflibercept-biosimilar-eyluxvir-alt-l9</link>
      <guid isPermaLink="true">https://6ix.com/company/alteogen-inc/news/alteogen-receives-positive-chmp-opinion-for-aflibercept-biosimilar-eyluxvir-alt-l9</guid>
      <pubDate>Mon, 28 Jul 2025 06:00:00 GMT</pubDate>
      <description>Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency&apos;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI® (code name: ALT-L9), a biosimilar referencing Eylea® (aflibercept), co-developed with its subsidiary Alteogen Biologics Inc.</description>
    </item>
  </channel>
</rss>